TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8292312
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (no treatment)
Study: 11549425
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) 600 mg/m2 (C)
Study: 26125735
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3D‐CRT + adjuvant chemotherapy)
Study: 8203335
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg three times daily
Study: 18800460
Drug: lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 20 mg
Study: 6446445
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (1500 mg)
Study: 12616578
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with exposure-based treatment
Study: 7048518
Drug: Hormonal treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal treatment alone with delayed chemotherapy until tumor progression
Study: 30220262
Drug: Carp pituitary
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carp pituitary extract (CPE; 2.0 mg/kg)
Study: 12122623
Drug: Lidocaine HCl
Normalized name: lidocaine HCl
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine HCl aerosol (4 mg/kg of 10% lidocaine HCl applied eight times daily)
Study: 30220262
Drug: NaCl solution
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaCl solution 0.9% (control group; 0.5 ml/kg)
Study: 7732992
Drug: Thrombolysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis with intravenous tissue plasminogen activator or urokinase
Study: 31992372
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (20 g/d)
Study: 18257603
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of donepezil (15 mg/day for weeks 1-12; 20 mg/day for weeks 13-24)
Study: 30558079
Drug: Loxonin tablet
DrugBank: Loxoprofen (DB09212)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Loxonin tablet (60 mg of loxoprofen)
Study: 29850244
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/day
Study: 17274520
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose sublingual specific immunotherapy with a 6-grass-pollen mixture
Study: 28498942
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU vitamin D daily
Study: 20535051
Drug: Simulated acupuncture
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated acupuncture treatment
Study: 8104730
Drug: Preoperative platelet-rich
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative platelet-rich plasma (PRP) 10 ml.kg-1
Study: 8472058
Drug: Absolute decrease
Normalized name: Honey Absolute
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absolute decrease in PEF of > or = 70 l.min‐1
Study: 10836664
Drug: Benzalkonium chloride
Normalized name: Benzalkonium Chloride
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzalkonium chloride vaginal capsule
Study: 29048187
Drug: Liquid nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid nicotine concentration of 36 mg/ml
Study: 29048187
Drug: Liquid nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid nicotine concentration of 0, 8, 18, or 36 mg/ml
Study: 16432825
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (flush ligation of sites of reflux, stripping of the long saphenous vein and multiple phlebectomies)
Study: 25935783
Drug: TrimoSan gel
Normalized name: Triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TrimoSan gel (applied vaginally twice weekly)
Study: 25935783
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel (standard pessary care)
Study: 10673309
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b plus 200 mg ketoprofen three times a week
Study: 19411529
Drug: Survey respondents
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Survey respondents comparing oral health to heart disease
Study: 16769582
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific VOD prophylaxis or therapy (Control)
Study: 2795401
Drug: Parent present
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent present during injection
Study: 11986448
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium nebulizer solution, 20 mg 4 times daily (n = 167)
Study: 1835292
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (0.036 mg)
Study: 3880993
Drug: Diltiazem 360
Normalized name: dilTIAZem 360 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 360 mg/day
Study: 29562937
Drug: Intermittent renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent renal replacement therapy (IRRT)
Study: 29562937
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapy (CRRT)
Study: 17060064
Drug: Diuretic (chlorthalidone)
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (chlorthalidone)
Study: 8123120
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg weekly and proguanil 100 mg daily
Study: 9196769
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg weekly and proguanil 200 mg daily
Study: 9257749
Drug: Ciprofloxacin 400
Normalized name: ciprofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 400 mg intravenously twice a day for 4 days (Group B)
Study: 29325799
Drug: Coexistence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coexistence of HCY ≥ 14.65 μmol/l and hs-CRP ≥ 1.90 mg/l
Study: 28092139
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy (OT)
Study: 3708119
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg furosemide tablet (Product 4)
Study: 2678652
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g paracetamol
Study: 28980198
Drug: Osmotic-release oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-release oral system methylphenidate (OROS-MPH)
Study: 9505993
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of valspodar (200 mg as a 2-hour infusion)
Study: 21797916
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel 10 g/day plus placebo pills
Study: 10718681
Drug: Gabapentin (GBP)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GBP) 1800 mg/day for 3 months
Study: 8808415
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy intervention program (2.5-hr, 10-week activity-based program)
Study: 29664801
Drug: Rectal Cancer
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Cancer Female Sexuality score (development and validation)
Study: 25107840
Drug: Cytokine-induced killer
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cytokine-induced killer (CIK) cell treatment
Study: 15201546
Drug: Lisinopril 10-20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10-20 mg
Study: 1563057
Drug: Epidural infusions
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusions of fentanyl combined with bupivacaine 0.1%
Study: 8217999
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 50 mg/day (n = 10)
Study: 29659405
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% hydroquinone (HQ) cream
Study: 26051348
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) containing 843 mg (‐)‐epigallocatechin‐3‐gallate (EGCG)
Study: 3708122
Drug: Single-unit tablets
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-unit tablets (control)
Study: 17355735
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Dronabinol 10-20 mg, Ondansetron 8-16 mg)
Study: 7557868
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg per os once a week for 6 months
Study: 30354935
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy (ART) plus chemotherapy
Study: 20185616
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy group
Study: 27096538
Drug: Separated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separated therapy (IPL followed by Nd:YAG treatment 3 days later)
Study: 26350171
Drug: Drug holiday
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug holiday of 2 to 3 years after 3 to 5 years of BP treatment
Study: 9278803
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same drugs except for ketamine)
Study: 21243762
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg, 3 times a week
Study: 22374612
Drug: Injection group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection group (DXM 2.5 mg injected by tympanic membrane puncture at intervals of 2 days for a total of 4 occasions, total 10.0 mg)
Study: 7525790
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with hyperthermia (group B)
Study: 25230154
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg baclofen
Study: 22054050
Drug: Lithium (0.6-1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (0.6-1.2 mEq/L)
Study: 22054050
Drug: Quetiapine (300-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300-800 mg/d)
Study: 1812432
Drug: Cuban vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuban vaccine against group B Neisseria meningitidis
Study: 9793614
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of tramadol (2 ml solution for injection, 100 mg)
Study: 9217894
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with saline
Study: 9217894
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with indomethacin (0.65 microgram/kg/min)
Study: 12482109
Drug: Pulsed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed estrogen therapy (Aerodiol) at a dose of 300 microg/day
Study: 2752040
Drug: TXB2 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TXB2 infusion at 1.0 ng.kg‐1.min‐1
Study: 29605029
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with fluorouracil, epirubicin, and cyclophosphamide
Study: 9475275
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (2.5 ng/kg/min)
Study: 11561228
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg valsartan
Study: 30973188
Drug: Dexamethasone 2
Normalized name: dexamethasone 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 2 mg
Study: 27993169
Drug: Individualized exercise
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized exercise prescription (ventilatory thresholds)
Study: 19194342
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort extract (900 mg TID)
Study: 12012144
Drug: Test product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product (60 mg) after high-fat American breakfast
Study: 8452109
Drug: Carboplatin 400
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks
Study: 19558539
Drug: Topiramate 100
Normalized name: topiramate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 100 mg/day
Study: 29521662
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin bolus dose of 340 IU/kg of ideal body weight (IBW)
Study: 29521662
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin bolus dose of 300 IU/kg of total body weight (TBW)
Study: 15784033
Drug: IFN monotherapy
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN monotherapy for 24 weeks (group A: long-term IFN therapy)
Study: 15784033
Drug: IFN monotherapy
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN monotherapy for 6 weeks (group B: short-term IFN therapy)
Study: 12422252
Drug: Lidocaine without
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine without preservative (active drug)
Study: 17848841
Drug: Somatropin Solution
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Somatropin Solution (Sandoz)
Study: 8154412
Drug: Myocardial infarction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocardial infarction (MI) with no treatment
Study: 16431305
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily
Study: 20054669
Drug: Response-oriented individualized
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response-oriented individualized induction therapy with idarubicin (IDR) 12 mg/m2 for 3 days and cytarabine (Ara-C) 100 mg/m2 for 7 days, with additional IDR and Ara-C if bone marrow on day 8 did not become hypocellular with less than 15% blasts.
Study: 31266412
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual education, cognitive rehabilitation training, and conventional treatment)
Study: 25407349
Drug: Clinical medication
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical medication reviews (CMRs) facilitated by an expert team (GP and pharmacist)
Study: 24584926
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (ABA) 125 mg/week
Study: 9424900
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy
Study: 1282588
Drug: Ro 42-5892
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 42-5892 (0.1 mg/kg) fast infusion
Study: 25000151
Drug: Labisia pumila
Normalized name: Ulmus pumila pollen
DrugBank: Ulmus pumila pollen (DB10362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labisia pumila var alata water extract (400 mg)
Study: 16429657
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg per day for 4 weeks before operation
Study: 28252528
Drug: Pravastatin 40
Normalized name: pravastatin 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 40 mg daily
Study: 15305887
Drug: gliclazide MR
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gliclazide MR 30-120 mg daily
Study: 15744631
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract (612 mg)
Study: 16023771
Drug: DTaP vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP vaccine injected in the buttock
Study: 9383806
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard-dose chemotherapy without GM-CSF)
Study: 16110227
Drug: In-patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient treatment (IP)
Study: 11793035
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (oral tacrolimus 0.2 mg/kg daily + oral prednisone)
Study: 30380948
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated equine estrogens (CEE) plus 100 mg micronized progesterone (MP)
Study: 30380948
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg CEE plus 100 mg MP
Study: 3203706
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg furosemide
Study: 16205336
Drug: Medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical care with and without physical therapy
Study: 7437261
Drug: Antipyrine in
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine in patients treated with antiepileptic drugs
Study: 9744695
Drug: Omeprazole infusion
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole infusion
Study: 29324595
Drug: Antimuscarinic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimuscarinic therapy (4-8 mg daily)
Study: 20688622
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4)
Study: 20688622
Drug: L-thyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-thyroxine (L-T4) + L-triiodothyronine (L-T3)
Study: 28417296
Drug: DPP4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP4 inhibitors
Study: 15794387
Drug: Oral pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral pirfenidone
Study: 26856808
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (same pump parameters as during baseline evaluation)
Study: 27044557
Drug: Intravenous thiamine
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous thiamine (200 mg)
Study: 25393038
Drug: Subconjunctival Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival Bevacizumab (1.25 mg/0.05 mL)
Study: 30408272
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Control group)
Study: 20851549
Drug: 30-min infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30-min infusion of meropenem
Study: 30326789
Drug: Caffeine (∼3 mg/kg)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (∼3 mg/kg)
Study: 31469238
Drug: Tocilizumab at
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab at 8 mg/kg/month
Study: 31469238
Drug: Etanercept at
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept at 50 mg/week